Over the past several years, fundamental notions about transplantation have changed to such a degree that even the once familiar term, bone marrow transplant, is becoming increasingly outdated. In Stem Cell Transplantation for Hematologic Malignancies, leading investigators and physicians/clinicans comprehensively survey the current state-of-the-art in hematopoietic stem cell transplantation for malignant disease. The authors focus on the indications and results of transplantation for acute leukemia, chronic myelogenous leukemia, lymphoma, multiple myeloma, and breast cancer, providing insight into the relative merits of transplant and nontransplant approaches to these disorders. Special attention is given to transplant-related complications, including the pathophysiology and clinical consequences of acute and chronic graft-vs-host disease (GVHD), delayed immune reconstitution leading to infectious complications, and organ damage to the lung and liver. Additional chapters address the sources of stem cells and the effects of graft manipulation used to eliminate residual contaminating tumor cells in autologous transplantation, or to reduce the number of T lymphocytes causing GVHD in allogenic transplantation. Also discussed are the role of donor lymphocyte infusions in the treatment and prevention of relapse after stem cell transplantation and their influence on the development of nonmyeloablative transplantation. Comprehensive and state-of-the-art, Stem Cell Transplantation for Hematologic Malignancies outlines the many exciting advances that are working toward realization today while fully explaining the process of stem cell transplantation for malignant disease
CONTENT
I. Transplant for Malignant Disease -- 1 Allogeneic and Autologous Stem Cell Transplantation for Acute Leukemia and Myelodysplasia in the Adult -- 2 Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia -- 3 Stem Cell Transplantation for Hodgkinโ{128}{153}s and Non-Hodgkinโ{128}{153}s Lymphomas -- 4 Autologous and Allogeneic Transplantation for Multiple Myeloma -- 5 Hematopoietic Progenitor Cell Transplantation for Breast Cancer -- II. Complications of Transplantation -- 6 Pathophysiology of Acute Graft-vs-Host Disease -- 7 Acute Graft-vs-Host Disease -- 8 Chronic Graft-vs-Host Disease After Transplantation -- 9 Immune Reconstitution After Allogeneic Transplantation -- 10 Infection in the Hematopoietic Stem Cell Transplant Recipient -- 11 EBV Lymphoproliferative Disease After Transplantation -- 12 Pathophysiology of Lung Injury After Hematopoietic Stem Cell Transplantation -- 13 Hepatic Veno-Occlusive Disease -- 14 Quality-of-Life Issues Posttransplantation -- III. Sources of Donor Stem Cells -- 15 Stem Cell Sources: Peripheral Blood Stem Cells and Bone Marrow for Allogeneic Transplantation -- 16 Allogeneic Unrelated Donor Blood and Marrow Transplantation -- 17 Haploidentical Stem Cell Transplantation -- 18 Umbilical Cord Hematopoietic Stem Cell Transplantation -- IV. Graft Engineering -- 19 Tumor Contamination of Stem Cell Products: The Role of Purging -- 20 T-Cell Depletion to Prevent Graft-vs-Host Disease -- V. Graft-vs-Tumor Effect -- 21 Donor Lymphocyte Infusions: Clinical Applications and the Graft-vs-Leukemia Effect -- 22 Nonmyeloablative Transplantation
